Auto Injector Market Size, Share, Opportunities, COVID-19 Impact, And Trends By Type (Disposable Auto-Injectors, Reusable Auto-Injectors), By Application (Rheumatoid Arthritis, Anaphylaxis, Multiple Sclerosis, Others), By End-User (Homecare Settings, Hospitals & Clinics), And By Geography - Forecasts From 2022 To 2027

Published:  Mar 2022 Report Code: KSI061611775 Pages: 134

The global auto-injector market is evaluated at US$48.034 billion for the year 2020 and is projected to grow at a CAGR of 19.05% to reach a market size of US$162.789 billion by the year 2027.

Auto-injectors are syringes accompanied by a spring-charged needle with a pre-charged dosage of drugs or medicine. The convenience and user-friendliness offered by auto-injectors are increasing the demand for auto-injectors over conventional syringes. Autoinjectors are widely preferred over conventional syringes as they reduce anxiety and panic in patients compared to conventional syringes. The increasing cases of chronic diseases have boosted the market growth of the global auto-injector market. One of the major factors increasing the popularity and acceptability of auto-injectors over conventional syringes is the reduced anxiety caused by auto-injectors in patients.  The pre-charged dosage of drugs in auto-injectors also increases the effectiveness and convenience of auto-injectors for medical practitioners. The percentage of errors reported in auto-injectors is lower than that of conventional syringes. The significant investments in research and technological developments in medical drug injection by major market players are also contributing to the market growth of the auto-injector market. The rising trend of home-based medical diagnosis and medical care also increases the demand for auto-injectors in the global market. The wide use of auto-injectors for the self-injection of epinephrine to prevent anaphylaxis is also boosting the market growth of auto-injectors as cases of anaphylaxis are increasing.

The outbreak of the COVID-19 pandemic had a positive impact on the market growth of auto-injectors. The lockdowns and isolations imposed by governments as a result of pandemic outbreaks mean all activities were focused on the home itself. Even medical diagnosis and medical care for lifestyle diseases and daily check-ups were also shifted to home-based medical diagnosis. The rising trend of home-based medical diagnosis has increased the market for auto-injectors in the global market. The difficulty in reaching hospitals during the pandemic made people rely on home-based medical diagnoses for lifestyle diseases and medication. The convenience and effectiveness offered by auto-injectors in-home healthcare increased the market demand for auto-injectors in the global market during the pandemic. The recharged doses in auto-injectors make it easier and more convenient for patients to self-administer drugs or medicine. However, the shutdown of manufacturing plants for auto-injectors during the lockdowns has hampered and lowered the growth rate of the global auto-injector market during the pandemic.

Rising cases of chronic diseases

The rising cases of chronic diseases are one of the major factors driving the market growth of auto-injectors in the global market. The increasing rate of anaphylaxis cases is pushing the market growth of auto-injectors as the drug for the treatment of anaphylaxis is usually self-administered to patients with the help of auto-injectors. According to the global overview of WAO (World Allergic Organisation), the percentage of anaphylaxis cases is mostly reported in adults compared to children.  Adults or older people affected by anaphylaxis mainly seek the support of self-administered auto-injectors for the dosage intake of drugs like epinephrine. According to PAHO (Pan American Health Organisation), about 2% of the total American population is facing the effects of anaphylaxis. The rising trend of home-based medical care for lifestyle diseases and others is also fuelling the market growth of auto-injectors compared to conventional syringes. The benefits offered by auto-injectors in self-administration and effectiveness in dosage quantity are pushing the market value of auto-injectors in the global market.

Investment in companies

The significant investments offered by major market players in injectors and self-injectors are giving potential to the market growth of auto-injectors in the global market. The research and developments taking place in drug dosage administration are technically enhancing and developing the sector of auto-injectors. The support offered by the government in research and development in the medical field is also resulting in the growth of the auto-injector market. The large investments and involvement of companies like Amgen and Antares pharma are also leading to enhancement and development in the field of autoinjectors.

North America accounted for the largest share

Geographically, the North American region accounts for the major market share in the global auto-injector market. The increasing cases of anaphylaxis, arthritis, and other diseases in which auto-injectors are widely used are fuelling the market growth of autoinjectors in the North American region. The market growth of the auto-injectors market is followed by the Asia-Pacific region.

Auto-Injector Market Scope:

Report Metric Details
 Market size value in 2020  US$48.034 billion
 Market size value in 2027  US$162.789 billion
 Growth Rate  CAGR of 19.05% from 2020 to 2027
 Base year  2020
 Forecast period  2022–2027
 Forecast Unit (Value)  USD Billion
 Segments covered  Type, Application, End-User, And Geography
 Regions covered  North America, South America, Europe, Middle East and Africa, Asia Pacific
 Companies covered Amgen, Antares Pharma, Becton Dickinson and Company, Eli Lilly and Company, Johnson and Johnson, Mylan N.V., Novartis AG, SHL Medical, Teva Pharmaceutical Industries Ltd, Ypsomed AG
 Customization scope  Free report customization with purchase

 

Market Segmentation

  • By Type
    • Disposable autoinjectors
    • Reusable autoinjectors
  • By Application
    • Rheumatoid Arthritis 
    • Anaphylaxis
    • Multiple sclerosis
    • Others
  • By End-user
    • Homecare settings
    • Hospitals & Clinics
  • By Geography
    • North America
      • USA
      • Canada
      • Mexico
    • South America
      • Brazil
      • Argentina
      • Others
    • Europe
      • Germany
      • France
      • UK
      • Others
    • Middle East and Africa
      • Saudi Arabia
      • UAE
      • Others
    • Asia Pacific
      • China
      • India
      • Japan
      • South Korea
      • Taiwan
      • Thailand
      • Indonesia
      • Others

Frequently Asked Questions (FAQs)

Q1. What will be the auto-injector market size by 2027?
A1. The auto-injector market is projected to reach a market size of US$162.789 billion in 2027.


Q2. What factors are anticipated to drive the auto-injector market?
A2. The rising cases of chronic diseases are one of the major factors driving the global auto-injector market growth.


Q3. What are the growth prospects for the auto-injector market?
A3. The global auto-injector market is projected to grow at a CAGR of 19.05% over the forecast period.


Q4. What is the size of the global auto-injector market?
A4. Auto-Injector Market was valued at US$48.034 billion in 2020.


Q5. Which region holds the largest market share in the nanotools market?
A5. Geographically, the North American region accounts for the major share of the global autoinjectors market.

1. Introduction
1.1. Market Definition
1.2. Market Segmentation


2. Research Methodology
2.1. Research Data
2.2. Assumptions


3. Executive Summary
3.1. Research Highlights


4. Market Dynamics
4.1. Market Drivers
4.2. Market Restraints
4.3. Porters Five Forces Analysis
4.3.1. Bargaining Power of End-Users
4.3.2. Bargaining Power of Buyers
4.3.3. Threat of New Entrants
4.3.4. Threat of Substitutes
4.3.5. Competitive Rivalry in the Industry
4.4. Industry Value Chain Analysis


5. Global Auto-Injectors Market Analysis, by Type
5.1. Introduction
5.2. Disposable autoinjectors
5.3. Reusable autoinjectors


6. Global Auto-Injectors Market Analysis, by Application 
6.1. Introduction
6.2. Rheumatoid Arthritis  
6.3. Anaphylaxis 
6.4. Multiple sclerosis 
6.5. Others


7. Global Auto-Injectors Market Analysis, by End-user 
7.1. Introduction
7.2. Homecare settings 
7.3. Hospitals & Clinics 


8. Global Auto-Injectors Market Analysis, by Geography
8.1. Introduction
8.2. North America
8.2.1. USA
8.2.2. Canada
8.2.3. Mexico
8.3. South America
8.3.1. Brazil
8.3.2. Argentina
8.3.3. Others
8.4. Europe
8.4.1. Germany
8.4.2. France
8.4.3. UK
8.4.4. Others
8.5. Middle East and Africa
8.5.1. Saudi Arabia
8.5.2. UAE
8.5.3. Others
8.6. Asia Pacific
8.6.1. China
8.6.2. India
8.6.3. Japan
8.6.4. South Korea
8.6.5. Taiwan
8.6.6. Thailand
8.6.7. Indonesia
8.6.8. Others


9. Competitive Environment and Analysis
9.1. Major Players and Strategy Analysis
9.2. Emerging Players and Market Lucrativeness
9.3. Mergers, Acquisitions, Agreements, and Collaborations
9.4. Vendor Competitiveness Matrix


10. Company Profiles 
10.1. Amgen
10.2. Antares Pharma
10.3. Becton Dickinson and Company
10.4. Eli Lilly and Company
10.5. Johnson and Johnson
10.6. Mylan N.V.
10.7. Novartis AG
10.8. SHL Medical
10.9. Teva Pharmaceutical Industries Ltd
10.10. Ypsomed AG

Amgen

Antares Pharma

Becton Dickinson and Company

Eli Lilly and Company

Johnson and Johnson

Mylan N.V.

Novartis AG

SHL Medical

Teva Pharmaceutical Industries Ltd

Ypsomed AG

Pricing

Explore Custom Options available with this study:

  •  Request customization
  •  Buy sections of the study
  •  Buy country specific report
  •  Request excel, Historical data
  •  Subscription inquiry
  •  Request special pricing

Our Value Proposition

Analyst Support

All our studies come with 2 months of analyst support.


Confidentiality

We are in compliance with the global privacy laws.

Connect With Us